



PRIOR AUTHORIZATION CRITERIA

BRAND NAME (generic)

DALIRESP (roflumilast)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Daliresp is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use

Daliresp is not a bronchodilator and is not indicated for the relief of acute bronchospasm.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

 The requested drug is being prescribed to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in a patient with severe COPD associated with chronic bronchitis and a history of exacerbations

REFERENCES

- 1. Daliresp [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; August 2017.
- AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed November 2017.
- 3. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed November 2017.